REVIEW PAPER
Primary immune thrombocytopenia in children
1
Department od Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland
Submission date: 2021-02-07
Acceptance date: 2021-03-02
Publication date: 2021-03-28
Pediatr Pol 2021;96(1):53-59
KEYWORDS
TOPICS
ABSTRACT
Primary immune thrombocytopenia (ITP) is usually a benign and self-limiting disease in children. Due to the complex pathogenesis involving different immunological processes, its course may be unpredictable. The goal of therapy is to prevent severe, dangerous bleeding, especially intracranial bleeding. In addition to purpura, i.e. ecchymoses and bruises on the skin, mucosal bleeding may occur, e.g. from nose, gums, excessive menstrual bleeding, as well as severe bleeding from the gastrointestinal or urinary tract. First-line therapy relies on glucocorticoids (GKS) or intravenous immunoglobulins (IVIgG). The next stage of treatment is the inclusion of other immunosuppressive drugs or cytotoxic drugs. The introduction of thrombopoietin receptor agonists (TPO-RAs) for the treatment of this disease has been the biggest progress over the past 20 years. TPO-RAs are treatment of choice for chronic ITP. Splenectomy is now reserved only for children with chronic ITP resistant to thrombopoietin receptor agonists..
REFERENCES (50)
1.
Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113: 2386-2393.
2.
Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. Am J Hematol 2009; 85: 174-180.
3.
Zawilska K. Samoistna plamica małopłytkowa – skala problemu. Acta Haematologica Polonica 2009; 40: 843-849.
4.
Zawilska K, Podolak-Dawidziak M, Chojnowski K, et al. Polskie zalecenia postępowania w pierwotnej małopłytkowości immunologicznej, opracowane przez Grupę ds. Hemostazy Polskiego Towarzystwa Transfuzjologów i Hematologów. Pol Arch Med Wewn 2010; 120 (supl.): 10-16.
5.
Nugent DJ. Immune Thrombocytopenic Purpura of Childhood. Hematology Am Soc Hematol Educ Program 2006: 97-103.
6.
British Committee for Standard in Haematology General Haematology Task Force (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596.
7.
Cecinati V, Principi N, Brescia L, et al. Vaccine administration and the development of immune thrombocytopenic purpura in children. Human Vaccines & Immunotherapeutics 2013; 9: 1158-1162.
8.
Bertuola F, Morando C, Menniti-Ippolito F, et al. Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy. Drug Saf 2010; 33: 65-72.
9.
Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus 2011; 9: 262-273.
10.
Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-186.
11.
Kuwana M. Helicobacter pylori-associated immune thrombocytopenia: Clinical features and pathogenic mechanisms. World J Gastroenterol 2014; 20: 714-723.
12.
Neefjes VM, Heijboer H, Tamminga RY. H. Pylori Infection In Childhood Chronic Immune Thrombocytopenic Purpura. Haematologica 2007; 92: 576.
13.
Arnold DM, Bernotas A, Nazi I, et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 2009; 94: 850-856.
14.
Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113: 1231-1240.
15.
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3: 3829-3866.
16.
O’Leary ST, Glanz JM, McClure DL, et al. The Risk of Immune Thrombocytopenic Purpura After Vaccination in Children and Adolescents. Pediatrics 2012; 129: 248-255.
17.
Provan D, Newland AC. Current Management of Primary Immune Thrombocytopenia. Adv Ther 2015; 32: 875-887.
18.
Jubelirer SJ, Harpold R. The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review. Clin Appl Thromb Hemost 2002; 8: 73-76.
19.
Brighton TA, Evans S, Castaldi PA, et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88: 194-201.
20.
Maślanka K, Sikorska A, Uhrynowska M, Konopka L. Autoprzeciwciała przeciwpłytkowe skierowane przeciw glikoproteinom płytek krwi GPIIb/IIIa i GPIb, a przebieg choroby i wyniki leczenia w małopłytkowościach samoistnych. Acta Haematol Pol 2006, 37: 241-248.
21.
Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112: 4003-4008.
22.
Psaila B, Petrovic A, Page LK, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009; 114: 4777-4783.
23.
Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost 2015; 13: 457-464.
24.
Neunert CE. Individualized treatment for immune thrombocytopenia: predicting bleeding risk. Semin Hematol 2013; 50: 55-57.
25.
McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103: 1364-1369.
26.
McMillan R, The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol 2007; 44 (4 Suppl 5): 3-11.
27.
Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009; 113: 6511-6521.
28.
Chow L, Aslam R, Speck ER, et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cel mediated responses that are differentially sensitive to therapy. Blood 2010; 115: 1247-1253.
29.
Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007; 92: 283-284.
30.
Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013; 50: 43-49.
31.
Olsson B, Andersson PO, Jacobsson S, et al. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005; 93: 139-144.
32.
Olsson B, Ridell B, Carlsson L, et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008; 112: 1078-1084.
33.
Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146: 585-596.
34.
Kuter DJ, Gernsheimer TB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin N Am 2009; 23: 1193-1211.
35.
Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118: 28-36.
36.
Vishnu P, Aboulafia DM. Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia. J Blood Med 2016; 7: 99-106.
37.
Bussel JB, Hsieh L, Buchanan GR, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia. Pediatr Blood Cancer 2015; 62: 208-213.
38.
Garzon AM, Mitchell WB. Use of thrombopoietin receptor agonists in childhood immune thrombocytopenia. Front Pediatr 2015; 3: 70.
39.
Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
40.
Yacobovich J, Revel-Vilk S, Tamary H. Childhood immune thrombocytopenia-who will spontaneously recover? Semin Hematol 2013; 50: 71-74.
41.
Grimaldi-Bensouda L, Nordon C, Leblanc T, et al. Childhood immune thrombocytopenia: A nationwide cohort study on condition management and outcomes. Pediatr Blood Cancer 2017; 64: e26389.
42.
Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113: 4834-4840.
43.
Pasquet M, Aladjidi N, Guiton C, et al; Centre de Référence National des Cytopénies Auto-immunes de l’Enfant (CEREVANCE). Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience. Br J Haematol 2014; 164: 266-271.
44.
Seidel MG, Urban C, Sipurzynski J, et al. High response rate but short-term effect of romiplostim in paediatric refractory chronic immune thrombocytopenia. Br J Haematol 2014; 165: 419-421.
45.
Imbach P, Mark Crowther M. Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia . N Engl J Med 2011; 365: 734-741.
46.
Ministerstwo Zdrowia: Leczenie pediatrycznych chorych na przewlekłą pierwotną małopłytkowość immunologiczną (ICD-10 D69.3); https://www.gov.pl/zdrowie/cho.... 2018, 2020.
47.
Al-Samkari H, Grace RF, Kuter DJ. The role of romiplostim for pediatric patients with immune thrombocytopenia. Ther Adv Hematol. 2020; 11: 2040620720912992.
48.
Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica 2013; 98: 875-880.
49.
Leo CA, Pravisani R, Bidinost S, et al. Postsplenectomy recurrence of idiopathic thrombocitopenic purpura: role of laparoscopic splenectomy in the treatment of accessory spleen. G Chir 2015; 36: 153-157.
50.
Nomura S. Advances in diagnosis and treatments for immune thrombocytopenia. Clin Med Insights Blood Disord 2016; 9: 15-22.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
